1. Study identification
EU PAS Register NumberEUPAS26363
Official titleImpact of EU label changes for hydroxyzine products: post-referral prescribing trends
Study title acronymNone
Study typeObservational study
Brief description of the studyTo evaluate the impact of the risk minimisation measures implemented in 2015 to manage the potential risk of QT interval prolongation and cardiac arrhythmia of hydroxyzine containing medicinal products authorised in the European Union (EU) in clinical practice.
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsMEMO
Department/Research groupMedicines Monitoring Unit
Organisation/affiliationUniversity of Dundee
Details of (Primary) lead investigator
Title Professor
Last name MacDonald
First name Thomas
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?6
NHS National Services Scotland, Glasgow, UK
University of Southern Denmark, Denmark
University of Strathclyde, Glasgow
Countries in which this study is being conducted
International study
Denmark
Netherlands
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed22/03/201822/03/2018
Start date of data collection01/07/201901/07/2019
Start date of data analysis
Date of interim report, if expected
Date of final study report23/08/201922/09/2019
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding schemeEuropean Medicines Agency100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name MacDonald
First name Thomas
Address line 1Medicines Monitoring Unit/Hypertension Research Centre
Address line 2Ninewells Hospital & Medical School
Address line 3Level 7
CityDundee
PostcodeDD1 9 SY
CountryUnited Kingdom
Phone number (incl. country code)441382383119
Alternative phone number441382383232
Fax number (incl. country code)441382643204
Public Enquiries
Title Professor
Last name MacDonald
First name Thomas
Address line 1Medicines Monitoring Unit/Hypertension Research Centre
Address line 2Ninewells Hospital & Medical School
Address line 3Level 7
CityDundee
PostcodeDD1 9 SY
CountryUnited Kingdom
Phone number (incl. country code)441382383119
Alternative phone number441382383232
Fax number (incl. country code)441382643204
6. Study drug(s) information
Single-Constituent (Substance INN)HYDROXYZINE
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects100000
Additional information
Estimate based on anticipated hydroxyzine exposures
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
Pharmacy dispensing records
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Effectiveness evaluation
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
The three main objectives are as follows: To determine prescription patterns of hydroxyzine containing products. To determine prescribers compliance with recommendations. To determine prescription patterns of alternative medicines prescribed in patients where hydroxyzine has previously been prescribed.
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Drug utilisation study
Time series analysis
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
The proposed primary analysis will address the three objectives given above using interrupted time series regression to fit time trends to each series of time period data for each country. Using regression modelling we will evaluate: (1) The baseline slope before the intervention time point; (2) The change in slope from the baseline trend to the post-intervention trend; (3) The immediate change associated with the intervention time point. The effect of the intervention for each country will be represented either by a step function, or by a continuous linear function representing gradual implementation (interrupted time series analysis). This choice, and whether it is necessary to model any trends prior to the intervention time point, will be decided on visual inspection of the data. The analysis will be done by data source initially, and only pooled if the statistical models do not differ significantly between data sources.